Cara Therapeutics (CARA) Misses Q2 EPS by 4c

Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.58), $0.04 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $6.93 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist